Jump to:

Jonine Bernstein

Attending Epidemiologist, Co-Program Leader Survivorship, Outcomes and Risk Program

Office Phone

646-888-8241

Email

bernstej@mskcc.org

Education

Yale University

Current Research Interests

Survivorship, Outcomes & Risk Program
Learn about Memorial Sloan Kettering’s Survivorship, Outcomes, and Risk Program, which brings together scientists who are dedicated to addressing both local and global issues related to cancer care, prevention, and survivorship.
Learn more

Dr. Bernstein is the Principal Investigator (PI) of the WECARE Study (Women’s Environmental, Cancer, and Radiation Epidemiology) which examines genetic susceptibility and radiation exposure in breast cancer. Current investigations involving this resource include studies of the roles of mutations in the ATM, BRCA1, BRCA2 , Chek2, TP53BPI, MDC1, Rad50, and MRN genes.  Recently, Dr. Bernstein was awarded a grant from NIH to conduct a multi-stage genome-wide association study (GWAS) which involves genome-wide screening of the existing WECARE Study cases and controls, and recruitment of a validation data set, in order to discover single-nucleotide polymorphism (SNPs) associated with second primary breast cancer and with radiation. This year the investigators have finished the screening and are currently involved in analyzing the results.

Postdoctoral Fellowship in Breast Cancer Epidemiology
We are seeking talented and motivated candidates for a post doctoral fellow position in our research group in Breast Cancer Epidemiology.
Learn more

In 2012,  Dr. Bernstein  received a grant award to  examine the role of  mammographic density as a risk factor  for contralateral breast cancer. In addition, Dr. Bernstein and Dr. Sara Olson are collaborating on an NIH-funded multi-center study, the GLIOGENE (Genetic Epidemiology of Glioma) Study, to characterize genes in familial and sporadic glioma cases. The Memorial Sloan Kettering team joins a large group in North America, Europe, and Israel on this endeavor with Melissa Bondy of MD Anderson as Principal Investigator.  Lastly Dr. Bernstein, along with Drs. Jennifer Brooks and Malcolm Pike, are working with Dr. Elizabeth Morris and other clinical colleagues examining background parenchymal enhancement (BPE) as seen on MRI as a biomarker of breast cancer risk. Dr. Bernstein serves as a member of the board of the American College of Epidemiology (ACE), the National Council on Radiation Protection and Measurement (NCRP),  the NCI Board of Scientific Counselors (BSC), the AACR Molecular Epidemiolgoy (MEG) Steering Committee,  and a member of the American Epidemiological Society (AES). In 2011, she was co-Chair of the Third North American Congress of Epidemiology which occurs every 5 years and is compromised of over 25 participating epidemiology societies. .

Publications

Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE, Langholz B, Thomas DC, Bernstein L, Lynch CF, Olsen JH, Malone KE, Mellemkjaer L, Borresen-Dale AL, Rosenstein BS, Teraoka SN, Diep AT, Smith SA, Capanu M, Reiner AS, Liang X, Gatti RA, Concannon P, The WECARE Study Collaborative Group. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women’s environmental cancer and radiation epidemiology study. J Natl Cancer Inst 2010; 102(7):475-483.

Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD Jr, Anton-Culver H, Bernstein JL. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010; 28(14):2404-2410.

Reiner AS, John E, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, Malone KE, Knight JA, Capanu M, Teraoka SN, Concannon P, Liang X, Figueiredo JC, Smith SA, Stovall M, Pike MC,  Haile RW, Thomas DC, Begg CB, The WECARE Study Collaborative Group, Bernstein JL. Risk of asynchronous contralateral breast cancer in non-carriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: A report from the WECARE Study. J Clin Oncol 2013; 31(4):433-9.

Bernstein JL,  Thomas DC, Shore R, Robson ME, Boice J, Stovall M, Andersson M, Bernstein L, Malone K, Reiner AS, Lynch C, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen J, Mellemkjaer L, Liang X, Diep A, Borg A, Concannon P, Haile RW, The WECARE Study Collaborative Group. Contralateral Breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study report. Eur J Cancer 2013. [In Press]

Read more

  1. Fischbein A, Thornton JC, Lilis R, Valciukas JA, Bernstein JL, Selikoff IJ. Zinc protoporphyrin, blood lead, and clinical symptoms in two occupational groups with low-level exposure to lead. Am J Ind Med 1980; 1:391-399.

  2. Fischbein A, Thornton J, Blumberg WE, Bernstein JL, Valciukas JA, Moses M, Davidow B, Kaul B, Sirota M. Selikoff I. Health status of cable splicers with low-level exposure to lead: Results of a clinical survey. Am J Public Health 1980; 70:697-700.

  3. Fischbein A, Thornton J, Wolff MS, Bernstein JL, Selikoff IJ. Dermatological findings in capacitor manufacturing workers exposed to dielectric fluids containing polychlorinated biphenyls (PCBs). Arch Environ Health 1982; 37:69-74.

  4. Salz J, Lee T, Jester J, Villasenor R, Steel D, Bernstein JL, Smith R. Analysis of incision depth following experimental radial keratotomy. Ophthalmology 1983; 90:655-659.

  5. Azen S, Hurt A, Steel D, Wilson J, Reinig J, Bernstein JL, Bedi M, Smith R. Effects of the shearing posterior intraocular lens on the corneal endothelium. Am J Ophthalmol 1983; 95:798-802.

  6. Salz J, Azen S, Bernstein JL, Caroline P, Villasenor R, Schanzlin D. Evaluation and comparison of sources of variability in the measurement of corneal thickness with ultrasonic and optical pachymeters. Ophthalmic Surg 1983; 14:750-754.

  7. Kilburn K, Warshaw R, Einstein K, Bernstein JL. Evidence for air-way disease in non-smoking asbestos workers. Arch Environ Health 1985; 40:293-295.

  8. Miller A, Thornton J, Bernstein JL, Selikoff I, Tierstein A.  Mean and instantaneous expiratory flows, FVC and FEV1: Prediction equations for non-smokers and smokers from a probability sample of Michigan, a large industrial state. Bull Eur Physiopathol Respir 1986; 22:589-597.

  9. Weinberger S, Kandall S, Doberczak T, Thornton J, Bernstein JL. Early weight change patterns in neonatal abstinence. Am J Dis Child 1986; 140:829-832.

  10. Penefsky Z, Wolfe J, Greengard O, Bernstein JL. Mechanical responses of developing Fisher rat heart. Effects of Steroid Hormone. J Dev Physiol 1986; 8:333-335.

  11. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 75(5 pt 2)1987; 4:80-92.

  12. Packer M, Lee WH, Medina N, Yushak M, Bernstein JL, Kessler PD. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol 1987; 10:1303-1311.

  13. Doberczak T, Thornton J, Bernstein JL, Kandall S. Impact of maternal drug dependency on birth weight and head circumference of offspring. Am J Dis Child 1987; 141:1163-1167.

  14. Lebovitz A, Byrne M, Bernstein JL, Strain J. Chronic occupational exposure to asbestos: More than medical effects? J Occ Med 1988; 30:49-50.

  15. Gottlieb SS, Baruch L, Kukin ML, Bernstein JL, Fisher ML, Packer M.  Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 1990; 16:827-831.

  16. Bernstein JL, Thompson WD, Risch N, Holford TR. The genetic epidemiology of second primary breast cancer. Am J Epidemiol 1992; 136:937-948.

  17. Bernstein JL, Thompson WD, Risch N, Holford TR.  Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 1992; 136:925-936.

  18. Dubrow R, Bernstein JL, Holford T. Age-period-cohort modeling of large bowel cancer incidence by anatomic sub-site and sex in Connecticut. Int J Cancer 1993; 53:907-913.

  19. Taioli E, Zhitkovitch A, Toniolo P, Bernstein JL, Blum R, Costa M. DNA-protein crosslinks as a biomarker of cis-platinum activity in cancer patients. Oncol Rep 1996; 3:439-444.

  20. Tartter PI, Pace D, Frost M, Bernstein JL. Delay in diagnosis of breast cancer. Ann Surg 1999; 229:91-96.

  21. Gammon M, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD. Cigarette smoking and other risk factors in relation to p53 expression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 1999; 8:255-263.

  22. Gammon M, Hibshoosh H, Terry M, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 1999; 8:413-419.

  23. Rosenstein BS, Phelps RG, Weinstock MA, Bernstein JL, Gordon ML, Kantor I, Lebwohl MG, Rudikoff D, Shelton R, Lebwohl MG. p53 mutations in basal cell carcinomas arising in routine users of sunscreens. Photochemistry and Photobiology 1999; 70:798-806.

  24. Bernstein JL, Lopez-Carillo L, Wang L. Epidemiology of HER-2/neu and p53 in breast cancer. Salud Publica Mex 41 Suppl 2 1999; S114-123.

  25. Drumea K, Levine E, Bernstein JL, Shank B, Green S, Kaplan E, Mandell L, Cropley J, Obropta J, Braccia I, Krupnik A, Rosenstein B. ATM heterozygosity and breast cancer: screening of 37 breast cancer patients for ATM mutations using a non-isotopic Rnase cleavage-based assay. Breast Cancer Res Treat 2000; 61:79-85.

  26. Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL. The consequence of undertreating breast cancer in the elderly. J Am Coll Surg 2001; 196:698-707.

  27. Atencio DP, Iannuzzi CM, Green S, Stock RG, Bernstein JL, Rosenstein BS. Screening breast cancer patients for ATM mutations and polymorphisms using denaturing high performance liquid chromatography. Environ Mol Mutagen 2001; 38:200-208.

  28. Bernstein JL, Seminara D, Børresen-Dale, A-L. Workshop on the epidemiology of the ATM gene: Impact on breast cancer risk and treatment, present status and future focus, Lillehammer, Norway, 29 June 2002. Breast Cancer Res 2002; 4:249-252.

  29. Bernstein JL, Thompson WD, Casey G, DiCioccio RA, Whittemore AS, Diep AT, Thakore SS, Vaziri S, Xue S, Haile RW. Comparison of techniques for the successful detection of BRCA1 mutations in fixed paraffin-embedded tissue. Cancer Epidemiol Biomarkers Prev 2002; 11:809-814.

  30. Britton JA, Kushi L, Morabia A, Bernstein JL, Shore R, Geringer W, Rohan T. The development of a questionnaire to assess past year physical activity in a multi-ethnic/racial urban population. Soc and Prev Med 2002; 47:178-194.

  31. Bernstein JL, Lapinski R, Lynch CF, Holford T, Thompson WD. Factors influencing mortality among young women with second primary breast cancer. Cancer 2002; 95:2051-2058.

  32. Bernstein JL, Teraoka S, Haile RW, Borreson-Dale AL, Rosenstein BS, Diep A, Atencio D, Teitelbaum S, Thompson WD, Bernstein L, Anton-Culver H, Malone K, Lynch CF, Boice Jr. JD, Gatti RA, Langholz BM, Olsen JH, Stovall M, Thomas D, Concannon PJ. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat 2003; 21:542-500.

  33. Bernstein JL, Lapinski, RH, Thakore SS, Doucette J, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology 2003; 14:552-558.

  34. Bernstein JL, Bernstein L, Thompson WD, Teitelbaum SL, Lynch CF, Boice JD Jr., Rosenstein BS, Børresen-Dale A-L, Gatti RA, Concannon PJ, Haile RW, and the WECARE Study Collaborative Group. ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. Br J Cancer 2003; 89:1513-1516.

  35. Bernstein JL, Langholz BM, Haile RW, Bernstein L, Thomas DC, Stovall M, Malone KE, Lynch CF, Olsen JH, Anton-Culver H, Shore RE, Boice Jr. JD, Berkowitz GS, Gatti RA, Teitelbaum SL, Smith SA, Rosenstein BS, Borresen-Dale, AL, Concannon P, Thompson WD. Research Design: Evaluating gene-environment interactions in the etiology of breast cancer—the WECARE Study. Breast Cancer Res 2004; 6:R199-R214.

  36. Cesaretti JA, Stock RG, Lehrer S, Atencio DA, Bernstein JL, Stone NN, Wallenstein S, Green S, Loeb K, Kollmeier M, Smith M, Rosenstein BS. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 2005; 61:196-202.

  37. Ioannidis JPA, Bernstein JL, Boffetta P, Danesh J, Dolan S, Hartge P, Hunter D, Inskip P, Jarvelin MR, Little J, Maraganore DM, Bishop JA, O’Brien TR, Petersen G, Riboli E, Seminara D, Taioli E, Uitterlinden AB, Vineis P, Winn DM, Salanti G, Higgins JP, Khoury MJ. A network of investigator networks in human genome epidemiology. Am J Epidemiol 2005; 162:302-304.

  38. Bernstein JL, Godbold J, Raptis G, Watson M, Levinson B, Aaronson SA, Fleming TP. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Ca Res 2005; 11:6528-6535.

  39. Bernstein JL, Concannon P, Langholz B, Thompson WD, Bernstein L, Stovall M, Thomas DC;WECARE Study Collaborative Group. Multi-center screening of mutations in the ATM gene among women with breast cancer—the WECARE Study. Radiat Res 2005; 163:698-699.

  40. Bernstein JL, Teraoka SN, John EM, Andrulis IL, Knight JA, Lapinski R, Olson ER, Wolitzer AL, Seminara D, Whittemore AS, Concannon P. The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev 2006; 15:348-352.

  41. Langholz B, Bernstein JL, Bernstein L, Olsen JH, Borresen-Dale AL, Rosenstein BS, Gatti RA, Concannon P. On the proposed association of the ATM variants 5557G>A and IVS38-8T>C and bilateral breast cancer. Int J Cancer 2006; 119:724-725.

  42. Ioannidis JPA, Gwinn M, Little J, Higgins JPT, Bernstein JL, Boffetta P, Bondy M, Bray MS, Brenchley PE, Buffler PA,Casas Jp, Chokkalingam A, Danesh J, Smith GD, Dolan S, Duncan R, Gruis NA, Hartge P, Hashibe M, Hunter Dj, Jarvelin Mr, Malmer B, Maraganore DM, Newton-Bishop JA, O’Brien TR, Petersen G, Riboli E, Salanti G, Seminara D, Smeeth L, Taioli E, timpson N, Uitterlinden AG, Vineis P, Wareham N, Winn DM, Zimmern R, Khoury MJ. Human Genome Epidemiology Network and the Network of Investigator Networks. A road map for efficient and reliable human genome epidemiology. Nat Genet 2006; 38:3-5.

  43. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P. Population-based estimates of breast cancer risk associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat 2006; 11:1122-1128.

  44. Goldfrank D, Chuai S, Bernstein JL, y Cajal TR, Lee JB, Alonso MC, Diez O, Baiget M, Kauff ND, Offit K, Robson M. Impact of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev 2006; 11:2311-2313.

  45. Seminara D, Khoury MJ, O’Brien TR, Manolio T, Gwinn ML, Little J, Higgins JP, Bernstein JL, Boffetta P, Bondy M, Bray MS, Brenchley PE, Buffler PA, Casas JP, Chokkalingam AP, Danesh J, Davey Smith G, Dolan S, Duncan R, Gruis NA, Hashibe M, Hunter D, Jarvelin MR, Malmer B, Maraganore DM, Newton-Bishop JA, Riboli E, Salanti G, Taioli E, Timpson N, Uitterlinden AG, Vineis P, Wareham N, Winn DM, Zimmern R, Ioannidis JP. Human Genome Epidemiology Network; the Network of Investigator Networks. The emergence of networks in human genome epidemiology: challenges and opportunities. Epidemiology 2007; 1:1-8.

  46. Langholz B, Thomas DC, Stovall M, Smith S, Boice JD, Shore RE, Bernstein JL. Analysis of radiation dose-response with tumor location and location-specific dose in the WECARE Study of second breast cancer. Radiation Research 2007; 167:358-359.

  47. Largent JA, Capanu M, Bernstein L, Langholz B, Mellemkjaer L, Malone KE, Begg CB, Haile RW, Lynch CF, Anton-Culver H, Wolitzer A, Bernstein JL. Reproductive history and risk of second primary breast cancer: the WECARE Study. Cancer Epidemiol Biomarkers Prev 2007; 5:906-911.

  48. Ho AY, Fan G, Atencio DP, Green S, Formenti SC, Haffty BG, Iyengar P, Bernstein JL, Stock RG, Cesaretti JA, Rosenstein BS. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69(3):677-684.

  49. Malmer B, Adatto P, Armstrong G, Barnholtz-Sloan J, Bernstein JL, Claus E, Davis F, Houlston R, Il’yasova D, Jenkins R, Johansen C, Lai R, Lau C, McCarthy B, Nielsen H, Olson SH, Sadetzki S, Shete S, Wiklund F, Wrensch M, Yang P, Bond My. Gliogene – an international consortium to understand familial glioma. Cancer Epidemiol Biomarkers Prev 2007; 9:1730-1734.

  50. Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, Boice JD Jr, Shore RE, Women’s Environment, Cancer and Radiation Epidemiology Study Collaborative Group, Bernstein JL. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 2008; 100(1):32-40.

  51. Begg CB, Haile RW, BorgA, Malone KE, Concannon P, Thomas DC,Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu H, Liang X, Hummer AJ, Sima C, Bernstein JL. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008; 299(2):194-201.

  52. Figueiredo JC, Bernstein L, Capanu M, Malone KE, Lynch CF, Anton-Culver H,  Stovall M, Børresen-Dale A, Haile RW, Bernstein JL, The WECARE Study Collaborative Group. Oral contraceptives, post-menopausal hormones and risk of asynchronous bilateral breast cancer: The WECARE Study Group. J Clin Oncol 2008; 26(9):1411-1418.

  53. Mellemkjær L, Dahl C, Olsen JH, Bertelsen L, Guldberg P, Christensen J, Børresen-Dale A-L, Stovall M, Langholz B, Bernstein L, Lynch CF, Malone KE, Haile RW, Andersson M, Thomas DC, Concannon P, Capanu M, Boice JD,  The WECARE Study Collaborative Group12, Bernstein JL. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.  Br J Cancer 2008; 98(4):728-733.

  54. Stovall M, Smith SA, Langholz BM, Boice JD, Shore RE, Andersson M, Buchholz TA, Capanu M, Bernstein L, Lynch CF, Malone KE, Anton-Culver H, Haile RW, Reiner A, Thomas DC, Bernstein JL. Dose to the contralateral breast from radiation therapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys 2008; 72:1021-1030.

  55. Concannon P, Haile RW, Børresen-Dale AL, Rosenstein BS, Gatti RA, Teraoka SN, Diep TA, Jansen L, Atencio DP, Langholz B, Capanu M, Liang X, Begg CB, Thomas DC, Bernstein L, Olsen JH, Malone KE, Lynch CF, Anton-Culver H, Bernstein JL; Women’s Environment, Cancer, and Radiation Epidemiology Study Collaborative Group. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res 2008; 68(16):6486-6491.

  56. Langholz B, Thomas DC, Stovall M, Smith SA, Boice JD, Jr., Shore RE, Bernstein L, Lynch CF, Zhang X, Bernstein JL. Statistical methods for analysis of radiation effects with tumor and dose location-specific information with application to the WECARE Study of asynchronous contralateral breast cancer. Biometrics 2009; 65(2):599-608.

  57. Knight JA, Bernstein L, Largent J, Capanu M, Begg CB, Mellemkjaer L, Lynch CF, Malone KE, Reiner AS, Liang X, Haile RW, Boice JD Jr; WECARE Study Collaborative Group, Bernstein JL. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women’s Environmental Cancer and Radiation Epidemiology Study. Am J Epidemiol 2009; 169(8):962-968.

  58. Khoury MJ, Bertram L, Boffetta P, Butterworth AS, Chanock SJ, Dolan SM, Fortier I, Garcia-Closas M, Gwinn M, Higgins JP, Janssens AC, Ostell J, Owen RP, Pagon RA, Rebbeck TR, Rothman N, Bernstein JL, Burton PR, Campbell H, Chockalingam A, Furberg H, Little J, O’Brien TR, Seminara D, Vineis P, Winn DM, Yu W, Ioannidis JP. Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol 2009; 170(3):269-279.

  59. Figueiredo JC, Haile RW, Bernstein JL. Oral contraceptives and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Current Breast Cancer Reports 2009; 1(3):139-147.

  60. Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, Lynch CF, Bertelsen L, Capanu M, Concannon P, Borg A, Børresen-Dale AL, Diep A, Teraoka S, Torngren T, Xue S, Bernstein JL. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat 2010; 120(1):175-183.

  61. Borg A, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L, Bernstein L, Tellhed L, Xue S, Olson ER, Liang X, Dolle J, Børresen-Dale AL, Bernstein JL. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat 2010; 31(3):E1200-1240.

  62. Poynter JN, Langholz B, Largent J, Mellemkjaer L, Bernstein L, Malone KE, Lynch CF, Borg A, Concannon P, Teraoka SN, Xue S, Diep AT, Törngren T, Begg CB, Capanu M, Haile RW; WECARE Study Collaborative Group, Bernstein JL. Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study. Cancer Causes Control 2010; 21(6):839-846.

  63. Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Törngren T, Diep A, Xue S, Bertelsen L, Liang X, Reiner AS, Capanu M, Malone KE; WECARE Collaborative Study Group. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 2010; 123(2):491-498.

  64. Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE, Langholz B, Thomas DC, Bernstein L, Lynch CF, Olsen JH, Malone KE, Mellemkjaer L, Borresen-Dale AL, Rosenstein BS, Teraoka SN, Diep AT, Smith SA, Capanu M, Reiner AS, Liang X, Gatti RA, Concannon P; The WECARE Study Collaborative Group. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women’s environmental cancer and radiation epidemiology study. J Natl Cancer Inst 2010; 102(7):475-483.

  65. Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD Jr, Anton-Culver H, Bernstein JL. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010; 28(14):2404-2410.

  66. Robertson LB, Armstrong GN, Olver BD, Lloyd AL, Shete S, Lau C, Claus EB, Barnholtz-Sloan J, Lai R, Il’yasova D, Schildkraut J, Bernstein JL, Olson SH, Jenkins RB, Yang P, Rynearson AL, Wrensch M, McCoy L, Wienkce JK, McCarthy B, Davis F, Vick NA, Johansen C, Bødtcher H, Sadetzki S, Bruchim RB, Yechezkel GH, Andersson U, Melin BS, Bondy ML, Houlston RS. Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation. Fam Cancer 2010; 9(3):413-421.

  67. Scheurer ME, Etzel CJ, Liu M, Barnholtz-Sloan J, Wiklund F, Tavelin B, Wrensch MR, Melin BS, Bondy ML, Bernstein JL, GLIOGENE Consortium. Familial aggregation of glioma: a pooled analysis. Am J Epidemiol. 2010; 172(10):1099-107.

  68. Figueiredo JC, Brooks JD, Conti DV, Poynter JN, Teraoka SN, Malone KE, Bernstein L, Lee WD,  Duggan DJ, Siniard A, Concannon P, Capanu  M, Lynch CF, Olsen JH, Haile RW and Bernstein JL. Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: Potential modifying effect of BRCA1/BRCA2 mutation carrier status. Breast Cancer Res Treat 2011; 127(3):819-29.

  69. Capanu M, Concannon P, Haile RW, Bernstein L, Malone KE, Lynch CF, Liang X, Teraoka SN, Diep AT, Thomas DC, Bernstein JL, The WECARE Study Collaborative Group, Begg CB. Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling. Genet Epidemiol 2011; 35(5):389-397.

  70. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA. Background Parenchymal Enhancement on Breast MRI and Breast Cancer Risk. Radiology 2011; 260(1):50-60.

  71. Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Thompson WD, Bernstein JL. Risk factors by molecular subtypes of breast cancer among a population-based study of women 56 years or younger. Breast Cancer Res Treat 2011; 130(2):587-97.

  72. Quintana MA, Bernstein JL, Thomas DC, Conti DV. Incorporating model uncertainty in detecting rare variants: the Bayesian risk index. Genet Epidemiol 2011; 35(7):638-49.

  73. Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, Il’yasova D, Schildkraut J, Sadetzki S, Johansen C, Bernstein JL, Olson SH, Jenkins RB, Yang P, Vick NA, Wrensch M, Davis FG, McCarthy BJ, Leung EH, Davis C, Cheng R, Hosking FJ, Armstrong GN, Liu Y, Yu RK, Henriksson R, The Gliogene Consortium, Melin BS, Bondy ML. Genome-wide high-density SNP linkage search for glioma susceptibility loci—results from the Gliogene Consortium. Cancer Res 2011; 71(24): 7568-75.

  74. Brooks JD, Teraoka SN, Reiner AS, Satagopan JM, Bernstein L, Thomas DC, Capanu M, Stovall M, Smith SA, Wei S, Shore RE, Boice, Jr. JD, Lynch CF, Mellemkjær L, Malone KE, Liang X, the WECARE Study Collaborative Group, Haile RW, Concannon P and Bernstein JL. Variants in activators and downstream targets of ATM, radiation exposure and contralateral breast cancer risk in the WECARE Study. Hum Mutat 2012; 33(1):158-64.

  75. Brooks JD, John EM, Mellemkjaer L, Reiner AS, Malone KE, Lynch CF, Figueiredo JC, Haile RW, Shore RE; The WECARE Study Collaborative Group, Bernstein JL, Bernstein L. Body mass index and risk of second primary breast cancer: The WECARE Study. Breast Cancer Res Treat 2012; 131(2):571-580.

  76. Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallee M, Tavtigian S, Concannon P, Foulkes WD, Bernstein L, Bernstein JL, Begg CB. Rare Germline Mutations in PALB2 and Breast Cancer Risk: A Population-Based Study.  Hum Mutat 2012; 33(4):674-80.

  77. Brooks JD, Boice JD, Jr, Stovall M, Reiner AS, Bernstein L, John EM, Lynch CF, Mellemkjær L, Knight JA, Thomas DC, Haile RW, Smith SA, Capanu C, The WECARE Collaborative Group, Bernstein JL, Shore RE. Reproductive status at first diagnosis influences risk of radiation-induced second primary contralateral breast cancer in The WECARE Study. Int J Radiat Oncol Biol Phys 2012.

  78. Haile RW, John E, Unger J, Cortessi, Gonzales M, Thompson P, Tucker KI, Ho G, Bondy M, Martinez E, Cook L, Cruz M, Wright J, Schwartz S, Blinder V, Hayes RB, Friedman Jimenez G, Monroe K, Thomas D, Boffetta P. A Review of Cancer in US Hispanic Populations. Cancer Prev Res 2012; 5: 150-163.

  79. Teraoka SN, Bernstein JL, Reiner AS, Haile RW, Bernstein L, Lynch CF, Malone KE, Stovall M, Capanu M, Liang X, Smith SA, Mychaleckyj J, Hou X, Mellemkjaer L, Boice Jr. JD, Siniard A, Duggan D, Thomas DC, The WECARE Study Collaborative Group, and Concannon P. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology (WECARE) study. Breast Cancer Res; 13(6):R114.

  80. Liu Y, Melin BS, Rajaraman P, Wang Z, Linet M, Shete S, Amos CI, Lau C, Scheurer ME, Armstrong GN, Houlston RS,  Hosking FJ, Claus EB, Barnholtz-Sloan J, Lai R, Il’yasova D, Schildkraut J, Sadetzki S, Johansen C, Bernstein JL, Olson SH, Jenkins RB, LaChance D, Vick NA, Wrensch M, Davis F, McCarthy BJ, Andersson U, Chanock S, The Gliogene Consortium, Bondy ML. Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma. Hum Genet 2012; 131(9):1507-1517.

  81. Sun* X, Vengochea*  J, Elston R, Chen Y, Amos C, Armstrong G, Bernstein JL, Claus E, Davis F, Houlston RS, , Il’yasova D, Jenkins RB, Johansen C, Lai R, Lau CC, Liu Y, McCarthy BJ, Olson S, Sadetzki S, Schildkraut J, Shete S, Vick NA, Wrensch M, Yang P, The Gliogene Consortium, Melin B, Bondy ML,  Barnholtz-Sloan J. A variable age of onset segregation model for linkage analysis, with correction for ascertainment, applied to glioma. Cancer Epidemiol Biomarkers Prev 2012; 21(12): 2242-51.

  82. Brooks JD,  Bernstein L, Teraoka S, Knight JA, Mellemkjær L,  John EM, Malone KE, Reiner AS, Lynch C, Concannon P, Haile RW, Bernstein JL.Variation in genes related to obesity, weight and weight change and risk of contralateral breast cancer in the WECARE Study population. Cancer Epidemiol Biomark Prev 2012; 21(12): 2261-7.

  83. Sadetzki S, Bruchim R, Oberman B, Armstrong GN, Lau CC, Claus EB, Barnholtz-Sloan JS, Ilyasova D, Schildkraut J, Johansen C, Houlston RS, Shete S, Amos CI, Bernstein JL, Olson SH, Jenkins RB, Lachance D, Vick NA, Merrell R, Wrensch M, Davis FG, McCarthy BJ, Lai R, The Gliogene Consortium, Melin BS, Bondy ML. Description of selected characteristics of familial Glioma patients - Results from the Gliogene Consortium. Eur J Cancer 2013 Jan 4; pii: S0959-8049(12)00894-5.

  84. Reiner AS, John E, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, Malone KE, Knight JA, Capanu M, Teraoka SN, Concannon P, Liang X, Figueiredo JC, Smith SA, Stovall M, Pike MC,  Haile RW, Thomas DC, Begg CB, The WECARE Study Collaborative Group, Bernstein JL. Risk of asynchronous contralateral breast cancer in non-carriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: A report from the WECARE Study. J Clin Oncol 2013; 31(4):433-9.

  85. Quintana MA, Schumacher F,Casey G, Bernstein JL, Li L, and Conti DV. Incorporating prior biologic information for high dimensional rare variant association studies. Hum Hered 2012; 74(3-4):184-95.

  86. Brooks JD, Teraoka S, Malone K, Haile R, Bernstein L, Lynch CF, Mellemkjaer L, Duggan D, Reiner AS, Lewinger J, Figueiredo J, Bernstein JL. Variants in tamoxifen metabolizing genes: A case-control study of contralateral breast cancer risk in the WECARE Study. Int J Mol Epidemiol Genet 2013; 4(1):35-48.

  87. Begg CB, Zabor E, Bernstein JL, Bernstein L, Press M, Seshan V. A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med 2013. [Submitted]

  88. Bernstein JL,  Thomas DC, Shore R, Robson ME, Boice J, Stovall M, Andersson M, Bernstein L, Malone K, Reiner AS, Lynch C, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen J, Mellemkjaer L, Liang X, Diep A, Borg A, Concannon P, Haile RW, The WECARE Study Collaborative Group. Contralateral Breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study report. Eur J Cancer 2013. [In Press]

  89. Brooks JD, Teraoka SN, Bernstein L, Mellemkjær L, Malone KE, Lynch CF, Haile RW, Concannon P, Reiner AS, Duggan DJ, Schiermeyer K, The WECARE Study Collaborative Group, Bernstein JL , Figueiredo JC. Common variants in genes coding for chemotherapy metabolizing enzymes, transporters and targets:  A case-control study of contralateral breast cancer risk in the WECARE Study. Cancer Causes Control 2013. [In Press]

  90. Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Friedman DN, Mubdi NZ, Henderson TO, Leisenring WM, Stovall M, Hammond S, Smith SA, Boice JD, Hudson MM, Diller LR, Bhatia S, Kenney L, Neglia JP, Begg CB, Robison LL, Oeffinger KC. Breast cancer after chest radiation therapy for a childhood cancer. NEJM 2013. [Submitted]

Book Chapters

  1. Gaudet MM, Brooks  JD, Robson ME, Bernstein JL. Genetic Epidemiology of Breast Cancer. In: Women and Health. Goldman, ed. Elsevier, Amsterdam. Chapter 73, p. 1-13, 2012.

 

My Events

My Projects

Related topics:

Press Release
Breast Cancer Risk Varies Substantially Among Women Who Are Carriers of BRCA1 and BRCA2 Gene Mutations